Figure 1: Change In Height (cm) From Randomization Visit By Scheduled Week (treatment Group Mean ± Standard Error Of The Mean) (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 01)
Montelukast Sodium
Product Images NDC 66116-503
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 66116-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Montelukast Sodium Structural Formula (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 02)
Figure 2: Fev1 Mean Percent Change From Baseline (u.s. Trial: Montelukast Sodium N = 406; Placebo N = 270) (anova Model) (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 03)
This text shows a table with the mean percent change from baseline for a placebo and Montelukast Sodium treatment at weeks 0, 3, 6, 9, 12, and 15. There is no further information on the context of this table.*
Montelukast Sodium Tablets 10mg #30 (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 04)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
